Loisios-Konstantinidis I, Cristofoletti R, Fotaki N, Turner DB, Dressman J. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. Case example: Naproxen. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2020;143:105170. https://doi.org/10.1016/j.ejps.2019.105170.

Article  CAS  Google Scholar 

Pepin XJH, Parrott N, Dressman J, Delvadia P, Mitra A, Zhang X, et al. Current state and future expectations of translational modeling strategies to support drug product development, manufacturing changes and controls: a workshop summary report. J Pharm Sci. 2020. https://doi.org/10.1016/j.xphs.2020.04.021.

Article  PubMed  Google Scholar 

FDA. Guidance for Industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. https://collections.nlm.nih.gov/catalog/nlm:nlmuid-101720038-pdf Accessed August 9 2022. 2017.

FDA. Guidance for Industry. Dissolution testing of immediate release solid oral dosage forms. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dissolution-testing-immediate-release-solid-oral-dosage-forms Accessed August 9 2022. 1997.

Grimstein M, Yang Y, Zhang X, Grillo J, Huang SM, Zineh I, et al. Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. Food and Drug Administration’s Office of Clinical Pharmacology. J Pharm Sci. 2019;108(1):21–5. https://doi.org/10.1016/j.xphs.2018.10.033.

Article  CAS  PubMed  Google Scholar 

Basu S, Lien YTK, Vozmediano V, Schlender JF, Eissing T, Schmidt S, et al. Physiologically based pharmacokinetic modeling of monoclonal antibodies in pediatric populations using PK-Sim. Front Pharmacol. 2020;11:868. https://doi.org/10.3389/fphar.2020.00868.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kostewicz ES, Aarons L, Bergstrand M, Bolger MB, Galetin A, Hatley O, et al. PBPK models for the prediction of in vivo performance of oral dosage forms. European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences. 2014;57:300–21. https://doi.org/10.1016/j.ejps.2013.09.008.

Article  CAS  PubMed  Google Scholar 

Orilissa™ (elagolix) [United States package insert]. North Chicago, IL: AbbVie Inc.; 2018.

Oriahnn™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules) [United States package insert]. North Chicago, IL: AbbVie Inc. ; 2020.

Elagolix multidiscipline review, US FDA Center for Drug Evaluation and Research. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213388Orig1s000MultidisciplineR.pdf. Accessed August 9, 2022.

Schlaff WD, Ackerman RT, Al-Hendy A, Archer DF, Barnhart KT, Bradley LD, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med. 2020;382(4):328–40. https://doi.org/10.1056/NEJMoa1904351.

Article  CAS  PubMed  Google Scholar 

Elagolix multidiscipline review, US FDA Center for Drug Evaluation and Research. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210450Orig1s000MultiD.pdf. Accessed August 9, 2022.

AbbVie Inc. A phase 3 study to evaluate the safety and efficacy of elagolix in combination with estradiol/norethindrone acetate in subjects with moderate to severe endometriosis-associated pain. ClinicalTrials.gov identifier: NCT03213457 (M14-702). Last updated February 16, 2022. https://clinicaltrials.gov/ct2/show/NCT03213457. Accessed 9 Aug 2022

Chiney MS, Ng J, Gibbs JP, Shebley M. Quantitative assessment of elagolix enzyme-transporter interplay and drug-drug interactions using physiologically based pharmacokinetic modeling. Clin Pharmacokinet. 2020;59(5):617–27. https://doi.org/10.1007/s40262-019-00833-6.

Article  CAS  PubMed  Google Scholar 

Shebley M, Polepally AR, Nader A, Ng JW, Winzenborg I, Klein CE, et al. Clinical pharmacology of elagolix: an oral gonadotropin-releasing hormone receptor antagonist for endometriosis. Clin Pharmacokinet. 2020;59(3):297–309. https://doi.org/10.1007/s40262-019-00840-7.

Article  CAS  PubMed  Google Scholar 

Pade D, Jamei M, Rostami-Hodjegan A, Turner DB. Application of the MechPeff model to predict passive effective intestinal permeability in the different regions of the rodent small intestine and colon. Biopharm Drug Dispos. 2017;38(2):94–114. https://doi.org/10.1002/bdd.2072.

Article  CAS  PubMed  Google Scholar 

Chen C, Wu D, Guo Z, Xie Q, Reinhart GJ, Madan A, et al. Discovery of sodium R-(+)-4-butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2008;51(23):7478–85. https://doi.org/10.1021/jm8006454.

Article  CAS  PubMed  Google Scholar 

Polepally AR, Ng JW, Salem AH, Dufek MB, Parikh A, Carter DC, et al. Assessment of clinical drug-drug interactions of elagolix, a gonadotropin-releasing hormone receptor antagonist. J Clin Pharmacol. 2020;60(12):1606–16. https://doi.org/10.1002/jcph.1689.

Article  CAS  PubMed  PubMed Central  Google Scholar 

AbbVie Inc. A phase II, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of NBI-56418 in subjects with endometriosis. ClincialTrials.gov identifier: NCT00619866 (NBI-56418). Updated September 7, 2018. https://clinicaltrials.gov/ct2/show/NCT00619866. Accessed 9 Aug 2022

Fiolka T, Van Den Abeele J, Augustijns P, Arora S, Dressman J. Biorelevant two-stage in vitro testing for rDCS classification and in PBPK modeling-case example ritonavir. J Pharm Sci. 2020;109(8):2512–26. https://doi.org/10.1016/j.xphs.2020.04.023.

Article  CAS  PubMed  Google Scholar